JHS Svendgaard Laboratories financials

·FMCG & RetailChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹30.4cr+29.5% on Q1 FY26
Net profit
₹1.1cr+3.3% on Q1 FY26
EBITDA margin
6.8%−0.3 pts on Q1 FY26
EPS
₹0.120.0% on Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue30.423.5+29.5%
EBITDA2.11.7+24.7%
EBITDA margin6.8%7.1%−0.3 pts
Profit before tax0.10.6−90.2%
Net profit1.11.1+3.3%
EPS₹0.12₹0.120.0%

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹30.4 crNet profit₹1.1 crNet margin3.6%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
71.6————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
3.83.86.79.139.4
0.00.00.00.07.9
14.814.85.13.60.4
82.6————
10910292.070.896.2
—+10.5%+29.9%−26.4%—
3.02.6−4.0−0.9−9.1
2.8%2.6%−4.4%−1.3%−9.5%
−4.4−4.9−12.0−7.3−16.6
−1.9−1.9−19.7−4.1−16.8
−1.7%−1.9%−21.4%−5.7%−17.4%
−₹0.22−₹0.22−₹2.26−₹0.46−₹1.77
—+90.3%−386.6%+73.8%—
—−2.7−5.2−9.118.9
—−12.8−9.8−23.7−1.1
−15.5−15.5−14.9−32.817.8
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

JHS₹8.19

JHS Svendgaard Laboratories Limited

· FMCG & Retail
₹ CrorePeersBAJAJCONPGHHMcap ₹71.6 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————71.6
- Cash, Equiv & ST Investments39.49.16.73.83.8
+ Minority Interest7.90.00.00.00.0
+ Total Debt0.43.65.114.814.8
Enterprise Value————82.6
Revenue96.270.892.0101.7108.6
Growth %, YoY—-26.4+29.9+10.5—
EBITDA-9.1-0.9-4.02.63.0
Margin %-9.46-1.32-4.362.572.79
EBIT-16.6-7.3-12.0-4.9-4.4
Net Income-16.8-4.1-19.7-1.9-1.9
Margin %-17.44-5.73-21.41-1.89-1.74
EPS, Adj (current shares)-1.77-0.46-2.26-0.22-0.22
Growth %, YoY—+73.8-386.6+90.3—
Cash from Operations18.9-9.1-5.2-2.7—
Capital Expenditures-1.1-23.7-9.8-12.8—
Free Cash Flow17.8-32.8-14.9-15.5-15.5
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

JHS Svendgaard Laboratories financials and key ratios

Prices at the previous close · figures from the company's filings with NSE

JHS Svendgaard Laboratories (NSE: JHS) had a market capitalisation of ₹71.6 crore at the previous close (₹8.19 a share) and a price-to-book ratio of 0.41. In FY26 its consolidated net loss was ₹1.9 crore on revenue of ₹102 crore; in Q1 FY27 (April–June 2026) it was ₹1.1 crore, up 3.3% year on year. Its debt-to-equity ratio was 0.08 on 31 March 2026. Promoters held 33.85% of the shares on 30 September 2026.

Share price used
₹8.19 · previous close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

JHS Svendgaard Laboratories at a glance · consolidated

Market cap
₹71.6 Crat ₹8.19 · previous close
PE ratio
n/aloss over the last 4 quarters
Price to book (PB)
0.41book value ₹19.98 a share
ROE (FY26)
−1.1%+10.4 pts vs FY25ROCE −2.7%
Debt to equity
0.08net cash ₹4.3 Cr
Promoter holding
33.85%unchanged vs 30 Jun 202630 September 2026
Net worth
₹175 Cr+1.1% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
−₹15.5 Cr
EPS (FY26)
−₹0.22

Questions

What is the JHS Svendgaard Laboratories PE ratio today?

JHS Svendgaard Laboratories' PE ratio is not meaningful at the previous close: its consolidated net profit over the last four quarters (Q2 FY26 to Q1 FY27) was a loss of ₹1.9 crore, and a price-to-earnings ratio needs positive earnings. Its market capitalisation was ₹71.6 crore at ₹8.19 a share.

What is the JHS Svendgaard Laboratories PB ratio (price to book value)?

JHS Svendgaard Laboratories' price-to-book (PB) ratio is 0.41 at the previous close: a market capitalisation of ₹71.6 crore divided by shareholders' equity (book value) of ₹175 crore on 31 March 2026. That is a book value of ₹19.98 per share against a share price of ₹8.19.

What is the JHS Svendgaard Laboratories net worth?

JHS Svendgaard Laboratories' net worth — shareholders' equity in its consolidated balance sheet — was ₹175 crore on 31 March 2026, up 1.1% from ₹173 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹71.6 crore at the previous close.

What is the JHS Svendgaard Laboratories market cap?

JHS Svendgaard Laboratories' market capitalisation was ₹71.6 crore at the previous close: 8.74 crore shares at ₹8.19 each.

Is JHS Svendgaard Laboratories debt free?

No. JHS Svendgaard Laboratories had borrowings of ₹14.8 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.08. Its cash and current investments were ₹19.1 crore, so it held net cash of ₹4.3 crore.

What is the JHS Svendgaard Laboratories EPS?

JHS Svendgaard Laboratories' basic earnings per share (EPS) were −₹0.22 in FY26, against −₹2.37 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to −₹0.23.

What is the JHS Svendgaard Laboratories debt to equity ratio?

JHS Svendgaard Laboratories' debt-to-equity ratio was 0.08 on 31 March 2026: borrowings of ₹14.8 crore against total equity of ₹175 crore. A year earlier, on 31 March 2025, it was 0.03.

What is the JHS Svendgaard Laboratories revenue and profit in FY26?

In FY26 (April 2025–March 2026), JHS Svendgaard Laboratories' consolidated net loss was ₹1.9 crore, narrower than the loss of ₹19.7 crore in FY25, on revenue from operations of ₹102 crore (up 10.5%).

When are the JHS Svendgaard Laboratories next results?

JHS Svendgaard Laboratories will announce its Q2 FY27 results (July–September 2026) on Monday, 2 November 2026, the date of the board meeting it has notified to the exchanges.

What is the JHS Svendgaard Laboratories ROE and ROCE?

In FY26, JHS Svendgaard Laboratories' return on equity (ROE) was −1.1% and its return on capital employed (ROCE) was −2.7%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was −11.5% and ROCE −6.8%.

How does JHS Svendgaard Laboratories compare with its peers?

On FY26 consolidated figures, against Bajaj Consumer Care: JHS Svendgaard Laboratories' operating margin of −4.8% is the lower of the two (Bajaj Consumer Care 17.7%; peer average 17.7%); its return on equity of −1.1% is the lower of the two (Bajaj Consumer Care 25.3%; peer average 25.3%); its revenue growth over three years of 1.9% a year is the lower of the two (Bajaj Consumer Care 6.6% a year; peer average 6.6% a year).

JHS Svendgaard Laboratories vs Bajaj Consumer Care: how do they compare?

In FY26, JHS Svendgaard Laboratories earned net profit of ₹1.9 crore on revenue of ₹102 crore, against ₹190 crore on ₹1,165 crore for Bajaj Consumer Care. JHS Svendgaard Laboratories' operating margin was −4.8% (Bajaj Consumer Care 17.7%) and its return on equity −1.1% (Bajaj Consumer Care 25.3%).

What is the JHS Svendgaard Laboratories book value per share?

JHS Svendgaard Laboratories' book value per share was ₹19.98 on 31 March 2026: shareholders' equity of ₹175 crore divided by the 8.74 crore shares in issue, down 1.0% from ₹20.18 a year earlier. The share price at the previous close was ₹8.19.

What is the JHS Svendgaard Laboratories promoter holding?

Promoters held 33.85% of JHS Svendgaard Laboratories on 30 September 2026, unchanged from the previous quarter and down 0.71 percentage points from 34.56% a year earlier, according to the shareholding pattern filed with NSE.

What is the JHS Svendgaard Laboratories shareholding pattern?

On 30 September 2026, JHS Svendgaard Laboratories' shares were held by promoters 33.85%, foreign portfolio investors (FII/FPI) 2.87% and retail and other non-institutional investors 63.28%. Over the year, FII holding was up 1.30 percentage points from 1.57%.

What is the JHS Svendgaard Laboratories free cash flow?

In FY26, JHS Svendgaard Laboratories generated ₹2.7 crore of cash from operations and spent ₹12.8 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹15.5 crore. In FY25 it was −₹14.9 crore.

What are the JHS Svendgaard Laboratories latest quarterly results?

JHS Svendgaard Laboratories' latest results are for Q1 FY27 (April–June 2026), filed on 11 August 2026: consolidated net profit ₹1.1 crore, up 3.3% from ₹1.1 crore in Q1 FY26; revenue from operations ₹30.4 crore, up 29.5% year on year.

Where do these JHS Svendgaard Laboratories figures come from?

From JHS Svendgaard Laboratories' own consolidated results, balance sheets and shareholding patterns filed with NSE. Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.